Related Experiment Video
Updated: Jun 1, 2026

Peptide Scanning-assisted Identification of a Monoclonal Antibody-recognized Linear B-cell Epitope
Published on: March 24, 2017
Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies
Esther J Witsch1, Georg Mahlknecht, Jean Wakim
1Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Abstract:
The erbb-2 gene receptor is often over-expressed in human cancer and its overexpression is accompanied by worse prognosis. Targeting erbb-2 gene with antibodies is an effective approach to curtail the progression of erbb-2 gene-expressing cancer types. Two monoclonal antibodies, L-26 and N-12, previously generated in our laboratory, have shown effective tumor inhibition in mice, especially when used in combination. Here, we describe novel peptide mimics of erbb-2 gene protein epitopes, also called mimotopes, that were selected from a constraint random 12-mer peptide phage library, specific for the antibodies L-26 and N-12. Initial sequencing analyses revealed little sequence conservation among the peptide mimotopes, and no sequence homology with the erbb-2 gene protein. However, computational analyses of the two groups of peptides, specific for L-26 and N-12, suggested different epitopes on the erbb-2 gene extracellular domain. In vitro assays showed that the phage displayed peptide mimotopes were specific to their respective antibodies. Selected cyclic peptide mimotopes, but not their corresponding linear equivalents, were able to inhibit binding of the antibodies L-26 and N-12 to the surface of erbb-2 gene-expressing cancer cells in a concentration-dependent manner. In line with this observation, phage-displayed cyclic peptides successfully competed in vitro with recombinant erbb-2 gene protein for binding to their respective antibodies L-26 or N-12. Consistent with the antibody inhibition experiments, we detected specific anti-erbb-2 gene antibodies following vaccination with KLH-coupled cyclic peptides but not with multiple antigenic linear peptides. Potentially, the selected peptides could serve as a starting point for the development of a vaccine against erbb-2 gene over-expressing cancer.
Insights
Novel peptide mimotopes targeting the erbb-2 gene receptor were developed. Cyclic versions of these mimotopes effectively inhibit antibody binding to cancer cells, showing potential for erbb-2 cancer vaccines.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- The erbb-2 gene receptor is over-expressed in human cancers, correlating with poor prognosis.
- Antibody-based therapies targeting erbb-2 are effective in inhibiting cancer progression.
- Monoclonal antibodies L-26 and N-12 have demonstrated tumor inhibition in preclinical models.
Purpose of the Study:
- To identify and characterize novel peptide mimotopes of erbb-2 gene protein epitopes.
- To evaluate the efficacy of these mimotopes in inhibiting antibody binding to erbb-2 expressing cancer cells.
- To explore the potential of these mimotopes as a basis for cancer vaccine development.
Main Methods:
- Selection of peptide mimotopes from a constrained random 12-mer peptide phage library specific for antibodies L-26 and N-12.
- Computational analysis to predict epitopes on the erbb-2 extracellular domain.
- In vitro assays to assess specificity, binding inhibition, and competition with recombinant erbb-2 protein.
- Vaccination studies in mice using KLH-coupled cyclic and linear peptides.
Main Results:
- Peptide mimotopes showed specificity for their respective antibodies (L-26 and N-12) without sequence homology to erbb-2.
- Cyclic peptide mimotopes, but not linear ones, inhibited antibody binding to erbb-2 expressing cancer cells in a dose-dependent manner.
- Cyclic peptides competed with erbb-2 protein for antibody binding and elicited specific anti-erbb-2 antibodies upon vaccination.
Conclusions:
- Novel cyclic peptide mimotopes targeting erbb-2 were identified.
- These cyclic mimotopes can block antibody-erbb-2 interactions and induce an immune response.
- The identified peptides represent a promising starting point for developing a vaccine against erbb-2 over-expressing cancers.
Related Concept Videos
Mitogens and the Cell Cycle
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

